Skip to main content
. Author manuscript; available in PMC: 2011 May 6.
Published in final edited form as: Gynecol Oncol. 2010 Oct;119(1):92–97. doi: 10.1016/j.ygyno.2010.06.012

Table 1.

Table 1a Characteristics of 136 patients in our population-based study.
Characteristics N/Total %
Montefiore Medical Center 57/136 41.9
Jacobi Medical Center 79/136 58.1
Age at procedure
 <30 24/136 17.7
 30–45 80/136 58.8
 >45 32/136 23.5
Race
 Black 56/118 47.5
 White 10/118 8.5
 Hispanic 36/118 30.5
 Other 16/118 13.6
Current smoker
 Yes 71/106 67.0
 No 35/106 33.0
Intravenous drug use
 Yes 21/99 21.2
 No 78/99 78.8
Parity
 Multiparous 44/48 91.7
 Nulliparous 4/48 8.3
Ever had an STD
 Yes 67/121 55.4
 No 54/121 44.6
Current hormone contraceptive use
 Yes 6/29 20.7
 No 23/29 79.3
Missed appointments
 Rarely (0–3) 39/89 43.8
 Frequently (3+) 50/89 56.2
Current HAART use
 Yes 57/111 51.4
 No 54/111 48.7
Table 1b Procedure and pathologic information for population-based study.
Characteristics N/Total %
First procedure type
 LEEP 93/136 68.4
 Cone 43/136 31.6
Procedure biopsy
 CIN 1 61/136 44.9
 CIN 2 47/136 34.6
 CIN 3 28/136 20.6
Margin status (endo- and ectocervical)
 Both positive 20/117 17.1
 Either positive 49/117 41.9
 Both negative 48/117 41.0
CD4 count at time of procedure (±8 weeks)
 ≤200 cells/µL 38/114 33.3
 201–500 cells/µL 56/114 49.1
 >500 cells/µL 20/114 17.5
Viral load at time of procedure (±8 weeks)
 Undetectable 55/122 45.1
 Detectable –20,000 copies/mL 35/122 28.7
 >20,000 copies/mL 32/122 26.2